CRYM
CRYM (crystallin mu) is a cytoplasmic ketimine reductase, also called ketimine reductase mu-crystallin, that uses NAD(P)H to reduce cyclic ketimine substrates. It is a taxon-specific crystallin that also binds thyroid hormone, and mutations in the gene are linked to DFNA40 deafness. Browse Assay Genie's current range of CRYM research reagents below, or read on for the biology behind the target.
CRYM catalyses the NAD(P)H-dependent reduction of imine double bonds in a number of cyclic ketimine substrates, including sulfur-containing cyclic ketimines. Under physiological conditions it efficiently reduces delta(1)-piperideine-2-carboxylate (P2C) and delta(1)-pyrroline-2-carboxylate (Pyr2C), which suggests a central role in lysine and glutamate metabolism. Further substrates include delta(2)-thiazoline-2-carboxylate (T2C), 3,4-dehydrothiomorpholine-3-carboxylate (AECK) and (S)-cystathionine ketimine (CysK). (R)-lanthionine ketimine is also accepted, but it is reduced at a very low rate compared with the other substrates.
The CRYM gene encodes a protein of the ornithine cyclodeaminase/mu-crystallin family, classed by HGNC among the oxidoreductases. Crystallins fall into two groups: ubiquitous crystallins, which are the major proteins of the vertebrate eye lens, and taxon-specific, or phylogenetically restricted, crystallins. CRYM belongs to the taxon-specific group. It binds NADPH and has sequence similarity to bacterial ornithine cyclodeaminases. Mouse and rat orthologs are both named Crym.
Unlike the lens crystallins, the encoded protein does not play a structural role in lens tissue. Instead it binds thyroid hormone, for possible regulatory or developmental roles. Mutations in this gene have been associated with autosomal dominant non-syndromic deafness, and the DFNA40 symbol reflects this link. The previous gene name was crystallin, mu.
CRYM efficiently reduces P2C and Pyr2C under physiological conditions, pointing to a central role in lysine and glutamate metabolism.
The enzyme acts on several cyclic and sulfur-containing ketimines with NAD(P)H, making it a model for studying substrate specificity in imine reduction.
CRYM binds thyroid hormone, and this activity is proposed to support regulatory or developmental roles distinct from any structural function.
Mutations in the CRYM gene are associated with autosomal dominant non-syndromic deafness, making it relevant to studies of inherited hearing loss.
CRYM is a ketimine reductase that uses NAD(P)H to reduce imine double bonds in cyclic ketimines. It efficiently reduces P2C and Pyr2C, suggesting a role in lysine and glutamate metabolism. It also binds thyroid hormone, for possible regulatory or developmental functions.
The HGNC name is crystallin mu, and the previous name was crystallin, mu. UniProt lists the protein as ketimine reductase mu-crystallin, and DFNA40 is a recorded alias, reflecting the link to autosomal dominant deafness. The enzyme is classified as EC 1.5.1.25.
Mouse and rat both have a Crym ortholog, so the gene is conserved in common model species. Mutations in human CRYM are associated with autosomal dominant non-syndromic deafness. Check the datasheet of any product for its validated reactivity.
Other crystallins, oxidoreductases and amino acid metabolism proteins with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q14894; product specifications from Assay Genie datasheets.